Dr. Flaherty is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Lawrence House 202
Boston, MA 02114Phone+1 617-643-5817Fax+1 617-724-3166- Is this information wrong?
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2002
- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
- Johns Hopkins University School of MedicineClass of 1997
Certifications & Licensure
- MA State Medical License 2009 - 2024
- FL State Medical License 2015 - 2017
- PA State Medical License 2000 - 2010
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- Boston Magazine Castle Connolly, 2010-2013
- America's Top Doctors for Cancer Castle Connolly, 2010-2013
- Join now to see all
Clinical Trials
- Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Start of enrollment: 2003 Oct 01
- Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2007 Sep 14
- Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer Start of enrollment: 2008 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.Xue Bai, Aleigha R Lawless, Juliane A Czapla, Stefanie C Gerstberger, Benjamin C Park, Seungyeon Jung, Rebecca Johnson, Naoya Yamazaki, Dai Ogata, Yoshiyasu Umeda, Cai...> ;JAAD International. 2024 Jun 1
- Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Ru...> ;JCO Precision Oncology. 2024 Apr 1
- Phase II Study of Erdafitinib in Patients With Tumors WithAmplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.Jun Gong, Alain C Mita, Zihan Wei, Heather H Cheng, Edith P Mitchell, John J Wright, S Percy Ivy, Victoria Wang, Robert C Gray, Lisa M McShane, Larry V Rubinstein, Dav...> ;JCO Precision Oncology. 2024 Apr 1
- Join now to see all
Journal Articles
- Effect of Capivasertib in Patients with an AKT1 E17K-Mutated TumorKevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
- Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic MelanomaGenevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
- A PAX3/BRN2 Rheostat Controls the Dynamics of BRAF Mediated MITF Regulation in MITFhigh/AXLlow MelanomaKeith T Flaherty, Jennifer A Wargo, Wiley
- Join now to see all
Press Mentions
- AACR Names Fellows of the AACR Academy Class of 2023April 7th, 2023
- AACR Announces Fellows of the AACR Academy Class of 2023 and New AACR Academy PresidentApril 6th, 2023
- NaNotics to Collaborate with Mass General Cancer Center on Novel NanomedicineSeptember 9th, 2022
- Join now to see all
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: